Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: Our experience and a review of the literature

Recent Results in Cancer Research

Volumn 194, Issue , 2013, Pages 385-393

  Treglia, Giorgio ^a   Castaldi, Paola ^a   Villani, Maria Felicia ^a   Perotti, Germano ^a   Filice, Angelina ^b   Ambrosini, Valentina ^c   Cremonini, Nadia ^d   Versari, Annibale ^b   Fanti, Stefano ^c   Giordano, Alessandro ^a   Rufini, Vittoria ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

Author keywords

Diagnosis; Medullary thyroid carcinoma; Neuroendocrine tumors; PET CT; Positron emission tomography

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE F18; GALLIUM 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; BONE METASTASIS; BONE SCINTISCANNING; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA;

EID: 84867049958     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27994-2_21     Document Type: Review

References (23)

1. Adams S, Baum RP, Hertel A et al (1998) Metabolic (PET) and receptor (SPET) imaging of welland less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19:641-647 (Pubitemid 28368315)
2. Ambrosini V, Marzola MC, Rubello D et al (2010) (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:46-48
3. Beheshti M, Pöcher S, Vali R et al (2009) The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: Comparison with 18F-FDG PET-CT. Eur Radiol 19:1425-1434
4. Beuthien-Baumann B, Strumpf A, Zessin J et al (2007) Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34:1604-1609 (Pubitemid 47476914)
5. Bodei L, Handkiewicz-Junak D, Grana C et al (2004) Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19:65-71 (Pubitemid 38352287)
6. Castellucci P, Pou Ucha J, Fuccio C et al (2011) Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med 52:886-890
7. Conry BG, Papathanasiou ND, Prakash V et al (2010) Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:49-57
8. Hoegerle S, Altehoefer C, Ghanem N et al (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71 (Pubitemid 32120808)
9. Jang HW, Choi JY, Lee JI et al (2010) Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: Comparison with (18)F-FDG PET/CT. Endocr J 57:1045-1054
10. Kebebew E, Ituarte PH, Siperstein AE et al (2000) Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139-1148 (Pubitemid 30127676)
11. Koopmans KP, de Groot JW, Plukker JT et al (2008) 18F- dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: Relation to tumor differentiation. J Nucl Med 49:524-531 (Pubitemid 351520599)
12. Marzola MC, Pelizzo MR, Ferdeghini M et al (2010) Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol 36:414-421
13. Pacini F, Castagna MG, Cipri C et al (2010) Medullary thyroid carcinoma. Clin Oncol 22: 475-485
14. Pałyga I, Kowalska A, Ga̧sior-Perczak D et al (2010) The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol 61:507-511
15. Papotti M, Kumar U, Volante M et al (2001) Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol 54: 641-649 (Pubitemid 34208908)
16. Pellegriti G, Leboulleux S, Baudin E et al (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88:1537-1542 (Pubitemid 36713778)
17. Reubi JC, Chayvialle JA, Franc B et al (1991) Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64:567-573
18. Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumours. Semin Nucl Med 36:228-247
19. Rufini V, Castaldi P, Treglia G et al (2008a) Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 62:139-146 (Pubitemid 351381932)
20. Rufini V, Treglia G, Perotti G et al (2008b) Role of PET in medullary thyroid carcinoma. Minerva Endocrinol 33:67-73
21. Rufini V, Treglia G, Castaldi P et al (2011) Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 32:575-82
22. Treglia G, Calcagni ML, Rufini V et al (2011) Clinical significance of incidental focal colorectal [(18) F]FDG uptake: Our experience and a review of the literature. Colorectal Dis. doi:10.1111/j.1463-1318.2011.02588.x
23. Versari A, Camellini L, Carlinfante G et al (2010) Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: A single-centre retrospective study. Clin Nucl Med 35:321-328